These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 15837308)

  • 1. Oximinoarylsulfonamides as potent HIV protease inhibitors.
    Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
    Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.
    Randolph JT; Huang PP; Flosi WJ; DeGoey D; Klein LL; Yeung CM; Flentge C; Sun M; Zhao C; Dekhtyar T; Mo H; Colletti L; Kati W; Marsh KC; Molla A; Kempf DJ
    Bioorg Med Chem; 2006 Jun; 14(12):4035-46. PubMed ID: 16504523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
    Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.
    Huang PP; Randolph JT; Klein LL; Vasavanonda S; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4075-8. PubMed ID: 15225729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
    Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
    J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
    Hou T; Yu R
    J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.
    Stranix BR; Lavallée JF; Sévigny G; Yelle J; Perron V; LeBerre N; Herbart D; Wu JJ
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3459-62. PubMed ID: 16644213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
    Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
    J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.
    Sherrill RG; Furfine ES; Hazen RJ; Miller JF; Reynolds DJ; Sammond DM; Spaltenstein A; Wheelan P; Wright LL
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3560-4. PubMed ID: 15975788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues.
    Nair AC; Miertus S; Tossi A; Romeo D
    Biochem Biophys Res Commun; 1998 Jan; 242(3):545-51. PubMed ID: 9464253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.
    Flosi WJ; DeGoey DA; Grampovnik DJ; Chen HJ; Klein LL; Dekhtyar T; Masse S; Marsh KC; Mo HM; Kempf D
    Bioorg Med Chem; 2006 Oct; 14(19):6695-712. PubMed ID: 16828558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
    Miller JF; Andrews CW; Brieger M; Furfine ES; Hale MR; Hanlon MH; Hazen RJ; Kaldor I; McLean EW; Reynolds D; Sammond DM; Spaltenstein A; Tung R; Turner EM; Xu RX; Sherrill RG
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1788-94. PubMed ID: 16458505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors.
    Adrian Meredith J; Wallberg H; Vrang L; Oscarson S; Parkes K; Hallberg A; Samuelsson B
    Eur J Med Chem; 2010 Jan; 45(1):160-70. PubMed ID: 19926360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic and thermodynamic characterization of HIV-1 protease inhibitors.
    Shuman CF; Hämäläinen MD; Danielson UH
    J Mol Recognit; 2004; 17(2):106-19. PubMed ID: 15027031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
    Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
    J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.